Recurrent ovarian clear cell adenocarcinoma
Clinical trials for Recurrent ovarian clear cell adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new Recurrent ovarian clear cell adenocarcinoma trials appear
Sign up with your email to follow new studies for Recurrent ovarian clear cell adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo shows promise in ovarian cancer fight
Disease control OngoingThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Matched conditions: RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Matched conditions: RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…
Matched conditions: RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Matched conditions: RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Matched conditions: RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC